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Abstract
Background: Arginase is significantly upregulated in the lungs in murine models of asthma, as well
as in human asthma, but its role in allergic airway inflammation has not been fully elucidated in mice.
Results: In order to test the hypothesis that arginase has a role in allergic airway inflammation we
generated arginase I-deficient bone marrow (BM) chimeric mice. Following transfer of arginase I-
deficient BM into irradiated recipient mice, arginase I expression was not required for
hematopoietic reconstitution and baseline immunity. Arginase I deficiency in bone marrow-derived
cells decreased allergen-induced lung arginase by 85.8 ± 5.6%. In contrast, arginase II-deficient mice
had increased lung arginase activity following allergen challenge to a similar level to wild type mice.
BM-derived arginase I was not required for allergen-elicited sensitization, recruitment of
inflammatory cells in the lung, and proliferation of cells. Furthermore, allergen-induced airway
hyperresponsiveness and collagen deposition were similar in arginase-deficient and wild type mice.
Additionally, arginase II-deficient mice respond similarly to their control wild type mice with
allergen-induced inflammation, airway hyperresponsiveness, proliferation and collagen deposition.
Conclusion: Bone marrow cell derived arginase I is the predominant source of allergen-induced
lung arginase but is not required for allergen-induced inflammation, airway hyperresponsiveness or
collagen deposition.
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Background
Asthma is a serious, chronic inflammatory disorder that is
responsible for one in six pediatric emergency room visits,
is the 3rd leading cause of hospitalization among children
and is one of the leading causes of school absenteeism. In
the United States, nearly 30% of the population suffers
from allergies with 5–10% inflicted with asthma. Despite
intense ongoing asthma research, there is currently an epi-
demic of this disease in the western world and the inci-
dence is on the rise [1,2]. The pathophysiology of asthma
is characterized by eosinophil-rich inflammatory cell
infiltrates, increased mucus production, airway hyperreac-
tivity, and reversible airway obstruction [3-5]. Experimen-
tation in the asthma field has largely focused on analysis
of the cellular and molecular events induced by allergen
exposure in sensitized animals (primarily mice) and
humans. While these studies have provided the rationale
for the development of multiple therapeutic agents that
interfere with specific inflammatory pathways [6], the
development of the asthma phenotype is likely to be
related to the complex interplay of a large number of addi-
tional genes, and their polymorphic variants.
Accordingly, in an effort to identify new genes involved in
the pathogenesis of asthma, we reported a group of genes
that was induced in the lungs in two phenotypically simi-
lar models of experimental asthma triggered by independ-
ent regimes [7,8]. Among these asthma signature genes,
we found overexpression of genes encoding for enzymes
and transporters involved in arginine metabolism, specif-
ically arginase I, arginase II and CAT2 [7]. We chose to
focus on these genes because intracellular arginine is a reg-
ulator of diverse pathways including production of nitric
oxide, polyamines, and proline; these molecules regulate
critical processes associated with asthma including airway
tone, cell hyperplasia and collagen deposition, respec-
tively [9,10]. Furthermore, recent studies have shown a
role for arginase in several parasitic models [11-16], com-
monly associated with Th2/M2 inflammation. Finally,
recent studies with arginase inhibitors suggested an effect
on outcomes of allergic airway inflammation in mice and
guinea pigs [17-19]. However, the results of these studies
were contradictory with one study suggesting a protective
and the other two a detrimental role for arginase in aller-
gen-induced inflammation and airway hyperresponsive-
ness. Altogether, we tested the hypothesis that arginase
expression has a role in allergic airway inflammation by
subjecting arginase I-deficient bone marrow chimeric
mice and arginase II-deficient mice to allergen challenge-
induced airway inflammation. We demonstrate that argi-
nase I expression does not affect bone marrow reconstitu-
tion following transfer into lethally irradiated recipients
and that arginase is not required for baseline immunity.
We also demonstrate that BM-derived arginase I is the
main source of allergen-induced lung arginase. However,
our studies demonstrate that arginase is not required for
allergen-induced airway inflammation, hyperresponsive-
ness or collagen deposition.
Methods
Generation of arginase I bone marrow (BM) chimeras
All animal studies were approved by the CCHMC IACUC
committee. Arginase I heterozygous mice [20] were bred
and pups were genotyped 7–9 days after birth. Bone mar-
row was collected from arginase I -/- pups and hetero-
zygous or wild type (majority of experiments) pups
(postnatal day 9–12). No difference was observed in
experiments where +/- versus +/+ mice were used as con-
trol. In early experiments we transferred 1 × 106 total bone
marrow cells, and in later ones 2 × 105 low density bone
marrow cells were used. No difference in engraftment was
observed with the two methods. Recipient mice (CD45.1
congenic mice) were irradiated [2 doses of 137Cs (700 and
475 rads) 3 hours apart] and bone marrow injected i.v.
Engraftment was checked by CD45.1 (recipient)/CD45.2
(donor) on peripheral blood by flow cytometry (antibod-
ies from BD Pharmingen specific for CD45.1 and CD45.2
are clones A20 and 104, respectively)) and allergen chal-
lenges started 8–14 weeks post-irradiation. In some exper-
iment, C57Bl/6 mice were used as recipients and thus
chimerism was not checked prior to the allergen chal-
lenge. However, in all experiments we verified that argin-
ase activity was not induced in the lung of allergen-
challenged arginase I BM chimeric mice (see results). As
an additional control, in some experiments we used mice
that were not irradiated and bone marrow transferred
(non-BMT). Finally, we backcrossed arginase I-hetero-
zygous mice for 6 generations on the BALB/c background
and verified findings obtained with C57Bl/6 mice (specif-
ically, the expression of arginase I in the lung by Northern
blot analysis, airway hyperresponsiveness and BALF cellu-
larity). Since congenic mice were not used to check
engraftment with BALB/c mice, we verified lack of argin-
ase I expression in the lung by Northern blot analysis.
Induction of allergic airway inflammation
Arginase I BM chimeras and Arginase II-deficient mice
[21] were allergen challenged using two models, as
described previously [7,8,22]. Briefly, in the first model,
mice were sensitized i.p. with ovalbumin (OVA, 100 μg)
in alum (1 mg) and challenged intranasally (i.n.) with 50
μg OVA or saline. Aspergillus fumigatus antigen-associated
asthma was induced by challenging mice intranasally
three times a week for three weeks, as described [23-25].
In brief, mice were lightly-anesthetized with isofluorane
inhalation and 100 μg (50 μl) of Aspergillus fumigatus
extract (Bayer Pharmaceuticals, Spokane, WA) or 50 μl of
normal saline alone was applied to the nasal cavity using
a micropipette with the mouse held in the supine posi-
tion. After instillation, mice were held upright until alert.
Mice were sacrificed 18–24 hours following the last chal-
lenge.BMC Immunology 2009, 10:33 http://www.biomedcentral.com/1471-2172/10/33
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Arginase activity
Arginase activity was measured using the blood urea nitro-
gen reagent (Sigma Chemical Company, St. Louis, MO)
according to established techniques [26-28].
In situ hybridization of mouse lung
In situ hybridization was performed as described [7]. In
brief, murine arginase I cDNA in plasmid pCMV-SPORT6
(Incyte Genomics, St. Louis, MO) was linearized by EcoRI
or Not I digestion, and anti-sense and sense RNA probes,
respectively, were generated by T7 and SP6 RNA polymer-
ase (Riboprobe Gemini Core System II transcription kit;
Promega, Madison, WI). The radiolabeled [αS35-UTP]
probes were hybridized and washed under high-strin-
gency conditions.
Northern blot analysis
RNA was extracted using the Trizol reagent as per the man-
ufacturer's instructions. The cDNA probes, generated by
PCR or from commercially available vectors [Image Con-
sortium obtained from American Tissue Culture Collec-
tion, Rockville, MD or Incyte Genomics, Palo Alto, CA],
were sequence confirmed, radiolabelled with 32P, and
hybridized using standard conditions, as described previ-
ously [7].
Measurement of airway hyperreactivity
Allergen-induced AHR was determined as described previ-
ously [29,30]. Briefly, mice were anesthetized, intubated
and ventilated at a rate of 120 breaths per minute with a
constant tidal volume of air (0.2 ml), and paralyzed with
decamethonium bromide (25 mg/kg). After establishing a
stable airway pressure, 25 μg/kg weight of acetylcholine
was injected i.v. and dynamic airway pressure (airway
pressure time index [APTI] in cm H2O/sec) was followed
for 5 minutes.
Measurement of collagen accumulation
Collagen accumulation was determined as described pre-
viously [31]. Briefly, the upper, left lobe of lung was
homogenized in 0.5 M acetic acid. Following the addition
of pepsin (1 mg/10 mg tissue, Sigma), the lung homoge-
nates were vigorously shaken overnight at 4°C. Collagen
content was determined biochemically by quantifying
total soluble collagen using the Sircol collagen assay kit
(Biocolor Ltd, Newtownabbey, Northern Ireland) accord-
ing to the manufacturer's instructions. The data are
expressed as the collagen content normalized per mouse
weight. In other experiments, we measured collagen accu-
mulation by measuring the content of hydroxyproline, as
previously described [32].
Antigen-specific antibody measurement
Plasma OVA-specific IgG1 was measured after coating the
wells with OVA (100 μg/ml). Blocking was done with
10% FBS in PBS, and all washes were performed with
0.1% Tween-20 in PBS. Plasma samples were diluted
1:1000 and then serially diluted 1:4. After 2 hours of incu-
bation, plates were washed and HRP-conjugated anti-
mouse IgG1 (1:1,500) (X56; BD PharMingen) was added.
The OD was read at 450 nm within 10 minutes.
Ki67 staining and quantification
Tissues were fixed in 10% neutral buffered formalin and
paraffin embedded. Immunohistochemistry analysis was
performed on deparaffinized 5 μm sections after blocking
of endogenous peroxidase activity, antigen retrieval (in cit-
rate buffer (pH6) in microwave oven for 7 min) and block-
ing with normal goat serum. The primary antibody [anti-
Ki67 1:50 (clone B56, BD PharMingen)] was diluted in
0.1% bovine serum albumin in PBS, applied to tissue sec-
tions, and incubated overnight at 4°C. Antibody staining
was detected with biotinylated anti-mouse IgG secondary
antibody and Vectastain ABC, MOM Immunodetection,
and DAB Substrate kits (Vector Laboratories, Inc.). Sections
were counterstained with nuclear fast red. Counts represent
evaluation of an average number of cells per mm2 deter-
mined by an observer blinded to treatment and genotype
using Metamorph software.
Statistical analysis
The significance of differences between groups were ana-
lyzed using two-way (disease and genotype) ANOVA
using Prism software. Values are reported as the mean ±
standard deviation. Differences are considered significant
if P < 0.05. Pairwise comparisons were performed by Stu-
dent's t-test and P values are shown in the figures.
Results
Development of arginase I-deficient bone marrow 
chimeras
Arginase I-deficient mice [20] develop severe hyperammon-
emia and die between postnatal days 10 and 14. Since we
have previously demonstrated that arginase I expression in
allergic airway inflammation is located in macrophages [7],
we developed bone marrow chimeras with arginase I-defi-
cient bone marrow derived from arginase I-deficient pups. In
experiments where congenic CD45.1 mice were used as
recipients, we evaluated donor (CD45.2) chimerism in the
peripheral blood at monthly intervals prior to commencing
allergen challenges. Importantly, there was no difference in
engraftment of arginase I-deficient and wild type bone mar-
row (for instance, in a representative experiment there were
92.14 ± 1.46 and 91.13 ± 2.64% donor-derived cells, respec-
tively; n = 7–8 mice, P = 0.38) demonstrating that arginase I
expression did not affect bone marrow reconstitution fol-
lowing bone marrow transfer.
Bone marrow-derived arginase I is not required for basal 
immunity
Since previous studies have demonstrated that arginase
transgenic mice have defective B cell maturation andBMC Immunology 2009, 10:33 http://www.biomedcentral.com/1471-2172/10/33
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impaired development of Payer's patches [33,34], we ana-
lyzed chimeric mice for basic hematological and immu-
nological parameters. We found that mouse body weight,
spleen weight, complete blood counts, engraftment of
individual cell types (CD4, CD8 and B220-positive cells)
were not dependent on arginase expression in BM-derived
cells (data not shown). Peyer's patches were not detecta-
ble macroscopically following irradiation irrespective of
arginase expression. In summary, we demonstrate that
bone marrow-derived arginase I is not required for base-
line immune cell development.
Bone marrow-derived arginase I is not required for 
adaptive immunity
7–14 weeks post-irradiation, mice were challenged with
allergen. We used two models of allergic airway inflam-
mation, as we have shown arginase I and II are increased
in both models and are part of the "asthma signature
genome" [7,8]. Importantly, while these two independent
models use different antigens and routes of sensitization,
the phenotype in mice is similar [7,8]. In the first model,
mice are sensitized intraperitoneally (i.p.) with OVA and
adjuvant alum and then challenged intranasally with OVA
or saline for control. In the second model, mice were sen-
sitized and challenged mucosally (by the intranasal route)
with Aspergillus fumigatus extract. First, we verified that
sensitization is not affected by arginase I deficiency. We
measured OVA-specific IgG1 in OVA-sensitized mice and
determined that deficiency of arginase I in bone marrow-
derived cells did not affect systemic sensitization (Figure
1A), which is consistent with our finding that the hemato-
logical and immunological parameters are grossly normal
in these mice. Similarly, OVA-specific IgE was not affected
by arginase I expression in bone marrow derived cells
(data not shown).
Bone marrow arginase I is the main source of allergen-
induced lung arginase
We hypothesized that bone marrow-derived cells are
required for arginase expression in the lung of allergen-
challenged mice. As seen in Figure 1B, Northern blot anal-
ysis for arginase I indeed shows decreased expression of
arginase I in arginase I chimeric mice (wild type mice
transplanted with arginase I-deficient bone marrow). Sim-
ilarly, in situ hybridization of allergen-challenged arginase
I-deficient BM chimeric mice demonstrated a significant
decrease in the number of arginase I-expressing cells com-
pared to mice that received arginase I +/- bone marrow
cells. (Figure 1C). In order to verify that the arginase I BM
chimeras indeed are deficient in lung arginase, we meas-
ured arginase activity in allergen-challenged mice. As
shown in Figure 1D, Aspergillus-challenged non-BMT
mice and arginase +/+ BM chimeras induce arginase activ-
ity in the lung. However, arginase I-deficient BM chimeras
did not show increased arginase activity with allergen
challenge. Similar results were seen in the OVA model
(data not shown). We have shown that both arginase I
and arginase II expression are increased in allergen chal-
lenged mice [7]. In order to test the hypothesis that argin-
ase I is the main contributor to the observed increase in
arginase activity in allergen-challenged mice, we meas-
ured arginase activity in allergen-challenged arginase II-
deficient mice. As seen in Figure 1E, arginase activity was
increased in the lungs of arginase II-deficient mice to a
level similar to wild type mice. In summary, these data
demonstrate that arginase I is primarily induced in bone
marrow-derived cells and that arginase I expression pre-
dominantly contributes to allergen-elicited arginase activ-
ity in the allergic lung.
Disease outcomes in allergic airway inflammation
We were first interested if arginase I has a role in inflam-
mation and cell recruitment in allergic airway inflamma-
tion. Cells in the BALF were differentiated based on
morphology and we demonstrate that arginase I BM chi-
meras had similar allergen-elicited recruitment of inflam-
matory cells (Figure 2A–B). Similar results were obtained
in arginase I-deficient BM chimeras on the BALB/c back-
ground with OVA and Aspergillus-induced allergic
inflammation. Furthermore, we assessed the expression of
cytokines and chemokines known to be induced by aller-
gen challenge. Northern blot analysis demonstrated
induction of eotaxin-2, TARC, 15-lypoxygenase and small
proline rich protein 2 (SPRR2) by OVA irrespective of argi-
nase I expression in the lungs (data not shown). Further-
more, the protein level of eotaxin-1, MIG, RANTES, IL-4,
IL-5 and leukemia inhibitory factor (LIF) were induced by
Aspergillus in the lungs of mice irrespective of arginase I
(data not shown). These data demonstrate that arginase I
is not required for the development of inflammation in
allergic lung inflammation.
Arginase can compete with NOS for substrate, arginine,
and can thus lead to decreased production of NO. As NO
has been shown to regulate airway tone, we tested the
hypothesis that arginase I has a role in allergen-induced
airway hyperreactivity (AHR). For these studies, we used
only the Aspergillus model which consistently induced
AHR in allergen-challenged C57Bl/6 mice. As seen in Fig-
ure 2C, Aspergillus-challenged non-BMT and arginase I +/
+ BM chimeras demonstrate increased responsiveness to
acetylcholine, compared to their respective saline-chal-
lenged controls. Interestingly, even in the absence of argi-
nase I activity in the lung, mice displayed AHR. Similar
results were obtained with arginase I-deficient BM chime-
ras on the BALB/c background. These data demonstrate
that arginase I is not required for allergen-induced AHR.
Arginase metabolizes arginine to urea and ornithine
which can further be metabolized by ornithine ami-BMC Immunology 2009, 10:33 http://www.biomedcentral.com/1471-2172/10/33
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Characterization of arginase I-deficient BM chimeric mice Figure 1
Characterization of arginase I-deficient BM chimeric mice. In A, OVA-specific IgG1 was measured in plasma. Repre-
sentative experiment (2–4 mice per group) of 3 experiments performed is shown. In B, Northern blot analysis for arginase I in 
allergen-challenged (OVA- ovalbumin model and Asp- Aspergillus fumigatus model) wild type and arginase I-deficient BM chime-
ras is shown. Ethidium bromide-stained gel is shown as loading control. In C, in situ hybridization with arginase I anti-sense 
probe is shown. Panels (a) and (b) are from an allergen-challenged arginase I +/- BM chimeric mouse and (c) and (d) are from an 
allergen-challenged arginase I -/- BM chimeric mouse. (a) and (c) are dark-field and (b) and (d) are bright-field images of the 
same area. Representative micrographs of 3 mice in each group are shown. In D and E, arginase activity on lung homogenates 
is shown. Representative of 4 experiments (2 with OVA and 2 with Asp) for arginase I chimeras, and 3 for arginase II-deficient 
mice are shown. Data are from 2–6 mice per group in the individual experiment with 7–15 total mice per group. For both argi-
nase I chimeras and arginase II-deficient mice, two-way ANOVA demonstrated a statistically significant (P < 0.01) effect of 
treatment (allergen compared to saline), with no statistically significant effect of interaction (P > 0.05). The P value for the 
effect of genotype was P = 0.055 in arginase I BM chimeras and P = 0.98 in arginase II-deficient mice.BMC Immunology 2009, 10:33 http://www.biomedcentral.com/1471-2172/10/33
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notransferase to proline, an amino acid that is often the
rate-limiting substrate for collagen synthesis [35-37].
Thus, we tested the hypothesis that arginase I has a role in
allergen-induced collagen deposition. For these studies,
we used only the Aspergillus model which demonstrates
significant allergen-induced collagen deposition. As seen
in Figure 2D, we observed increased collagen deposition
in non-BMT mice, as well as in arginase I-deficient and
sufficient BM chimeras. On average, there was a 39.2 ± 5%
and 58.8 ± 9% allergen-induced increase in wild type and
arginase I-chimeric mice, respectively (P = 0.47, n = 10–16
mice per group). These data demonstrate that arginase I is
not required for allergen-induced collagen accumulation.
Ornithine, the metabolite of arginase activity, can serve as
substrate for ornithine decarboxylase, leading to produc-
tion of polyamines, which plan an important role in pro-
liferation of cells. Thus, we tested the hypothesis that
arginase I has a role in allergen-induced cell proliferation.
As seen in Figure 2E–F, we observed increased numbers of
Ki67-positive cells in allergen-challenged mice. These lev-
els were comparable irrespective of arginase expression.
Thus, these data demonstrate that arginase I is not
required for allergen-induced proliferation.
Arginase II- deficient mice
It remained possible that arginase II is the critical arginase
isoform in outcomes of allergic lung inflammation. The
subcellular localization and presumed function of the two
isoforms is different with arginase II expressed in the
mitochondria (while arginase I is cytoplasmic) and pre-
dominantly implicated in biosynthetic pathways (while
arginase I is predominantly thought to be involved in the
urea cycle). Thus, we allergen challenged arginase II-defi-
cient mice [21] and analyzed for outcomes of allergic air-
way inflammation. As seen in Figure 3A, arginase II-
deficient mice had allergen-induced BALF cell accumula-
tion comparable to arginase II-wild type mice. Similarly,
the arginase II-deficient mice had levels of allergen-
induced airway hyperreactivity similar to wild type mice
(Figure 3B). Furthermore, collagen deposition was
induced in arginase II-deficient mice to levels comparable
to those of arginase II-wild type mice (Figure 3C). Finally,
proliferation of cells was not affected by the presence of
arginase II (Figure 3D). Importantly, arginase activity in
the lung was induced to similar levels in arginase II-defi-
cient and wild type mice (Figure 1E). Thus, these data
demonstrate that arginase II is not required for allergen-
induced airway inflammation, AHR, collagen deposition
and proliferation.
Discussion
The alternative pathway of macrophage activation, via IL-
4, has been recently appreciated in many Th2-associated
responses, such as parasitic infections and allergic inflam-
mation. However, the role of these cells and their effectors
in the broad spectrum of Th2-associated pathological
processes is poorly understood. We investigated the role
of the enzyme arginase, which is a marker of alternatively
activated macrophages and highly upregulated in allergic
and parasitic infection. While the role of arginase in the
urea cycle is well understood, its role in inflammation is
less clear. Based on known downstream mediators, argin-
ase has been speculated to play a role in NO production
and subsequent inflammation and regulation of airway
tone, as well as proliferation and collagen synthesis via
ornithine production. We used arginase I-deficient bone
marrow chimeric mice in models of allergic airway
inflammation. Use of arginase I BM chimeric mice
revealed several novel findings. First, we demonstrate that
arginase I expression does not affect bone marrow recon-
stitution following transfer into lethally irradiated recipi-
ents and that arginase is not required for baseline
immunity. Second, we demonstrate that BM-derived argi-
nase I is the main source of allergen-induced lung argin-
ase. Third, we found that lung arginase is dispensable for
regulation of inflammation, airway tone, fibrosis and cell
proliferation during allergic airway inflammation.
Studies using arginase transgenic mice have demonstrated
that overexpression of arginase (specifically in gut epithe-
lial cells) leads to interrupted development of B cells and
impaired Peyer's patch architecture [33,34]. Mechanistic
analysis suggested that the hypoargininemia was respon-
sible for the phenotype as arginine supplementation
reversed the changes. Thus, it was important to assure that
extrahepatic arginase deficiency does not perturb bone
marrow engraftment and baseline immune parameters.
We show here that genetic deficiency of arginase in bone
marrow-derived cells does not affect BM engraftment,
baseline and adaptive immunity. Thus, we speculate that
excessive and/or systemic expression of arginase, such as
in transgenic mice overexpressing arginase may affect the
immune system via decreasing systemic arginine levels;
however, lack of extrahepatic arginase does not appear to
grossly affect the immune system.
Previous studies have suggested that macrophages are the
main source of arginase in the allergen challenged mouse
lung. However, other cell types, including respiratory epi-
thelial cells have been implicated as potential sources of
arginase [7,38-40]. Furthermore, we and others have
shown that both arginase I and II expression is increased
in the lungs following allergen challenge [7]. Thus, it
remained possible that arginase II will contribute to lung
arginase activity in allergen challenged arginase I BM chi-
meric mice. Our studies measuring arginase activity in
both arginase I BM chimeric and arginase II-deficient mice
demonstrated that arginase I, expressed in bone marrow
cells, is the main contributor to arginase activity in allergicBMC Immunology 2009, 10:33 http://www.biomedcentral.com/1471-2172/10/33
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Disease outcomes in arginase I-deficient BM chimeric mice Figure 2
Disease outcomes in arginase I-deficient BM chimeric mice. In A and B, cell composition of the BALF is shown from 
OVA and Aspergillus model experiments. Data are from 2–4 (OVA model) and 3–11 (Asp model) mice per group. In C, airway 
hyperresponsiveness is shown. Data are from 3–6 mice per group. In D, collagen content of the lung is shown. Data are from 
4–6 mice per group. In E and F, quantification of Ki67-positive cells by immunohistochemistry in Asp and OVA model respec-
tively, is shown. Data are from 2–6 mice/group. In C-F, two-way ANOVA demonstrated a statistically significant (P < 0.001) 
effect of treatment (allergen compared to saline), with no statistically significant effect of genotype or interaction (P > 0.05). In 
each panel, a representative experiment out of three performed is shown.BMC Immunology 2009, 10:33 http://www.biomedcentral.com/1471-2172/10/33
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lung. These data support the notion that bone marrow-
derived cells, such as infiltrating inflammatory macro-
phages, are the main source of the arginase I enzyme, and
arginase activity in the allergic lung.
We originally hypothesized that arginase induction has a
role in the pathophysiology of allergic airway inflammation.
This was based on several findings. First, we and others have
shown that arginase expression and function is increased in
the lungs of allergen challenged mice and in the lungs and
serum of humans with asthma [7,41]. However, these stud-
ies did not address the specific role of arginase in pathophys-
iology of the disease. Second, downstream pathways of
arginase have been implicated in the regulation of inflam-
mation, collagen deposition, proliferation and airway hyper-
responsiveness [35,42,43]; these are all hallmark outcomes
in asthma. Specifically, Meurs et al have elegantly demon-
strated a role for arginase in contractility of allergen-chal-
lenged guinea pig tracheas ex vivo. They have also
demonstrated that the mechanism for this effect includes
arginase-mediated decrease of NO production [44,45].
These results, obtained in guinea pigs and in reductionist ex
vivo approaches, differ from our data that were obtained in
the complex in vivo environment of allergen challenged
mice. We speculate that the difference lies either in the
model system (guinea pigs versus mice) or that parallel path-
ways are invoked in vivo during allergen challenge, thus mak-
ing the role of arginase redundant. Third, mouse models of
parasite infestation, including Schistosome mansoni, Helig-
mosomoides polygyrus, Leishmania sp, Toxoplasma gondii
Disease outcomes in arginase II-deficient mice Figure 3
Disease outcomes in arginase II-deficient mice. In A, cell composition of the BALF is shown. Data are from 3–4 mice per 
group. Representative experiment of 5 (2 with Aspergillus and 3 with OVA model) is shown. In B, airway hyperresponsiveness 
is shown. Data are from 4–6 mice per group. In C, collagen content of the lung is shown. Data are mean ± SD of 4–6 mice per 
group. In D, quantification of Ki67-positive cells by immunohistochemistry is shown. Data are from 2–5 mice/group. In B-D, 
two-way ANOVA demonstrated a statistically significant (P < 0.001) effect of treatment (allergen compared to saline), with no 
statistically significant effect of genotype or interaction (P > 0.05). In B-D, a representative experiment of two performed is 
shown.BMC Immunology 2009, 10:33 http://www.biomedcentral.com/1471-2172/10/33
Page 9 of 11
(page number not for citation purposes)
and Nipostrongylus brasiliensis [11-16] demonstrated a role
for arginase expression in host defense. Interestingly, in at
least one of those publications the role of arginase was con-
fined to models of infection by intracellular pathogens; how-
ever, arginase did not play a role in a systemic disease despite
induction of arginase in both models [16]. Finally, we have
shown a role for arginase in IL-13 induced airway hyperre-
sponsiveness [46] and others have recently suggested a role
for arginase in mouse and guinea pig asthma models using
arginase inhibitors [17-19]. Specifically, we have shown that
delivery of arginase I siRNA to mice that receive IL-13 i.t.
leads to decreased arginase I expression and airway respon-
siveness. It is important to note that this effect was observed
at early time points (12–48 hours following single i.t. instal-
lation of IL-13). Thus, we speculate that arginase may play a
role in airway responsiveness to a single cytokine at early
time points when collateral pathways have not been able to
develop; in contrast, in allergen challenge multiple pathways
are activated that may contribute to airway responsiveness
thus making arginase redundant. The study by Maarsingh et
al [18], demonstrated that inhalation of ABH, an inhibitor of
arginase, protects against allergen-induced airway obstruc-
tion, hyperresponsiveness and inflammation. We speculate
that our results differ from the ones in this study either
because of the different species used (mice versus guinea
pigs) or because of the different approach (inhibitors versus
genetic ablation of arginase). It is possible that the inhibitor
has non-specific off-target effects that may be responsible for
the observed effects. It is important to note that arginase
plays an important role in the urea cycle in the liver; muta-
tions in arginase leads to severe metabolic consequences in
humans and mice, including hyperargininemia, hyperam-
monemia and premature death [20,47]. In an effort to con-
firm our results, we used an inhibitor of arginase, BEC, and
found that it leads to systemic effects, including hyperar-
gininemia (data not shown). Since plasma arginine levels
can have profound effects on the immune system [33,34,48-
54], we elected not to pursue studies with inhibitors as we
believed we could not distinguish the effects of arginase inhi-
bition locally in the lungs from indirect effects from arginase
inhibition in the liver. In contrast to the study by Maarsingh
et al where arginase inhibitor decreased inflammation and
airway hyperresponsiveness, Ckless et al [17], found that
inhibitor of arginase led to increased inflammation and air-
way hyperresponsiveness in mouse models of allergic
inflammation. Together, these data caution against use of
arginase inhibitors in allergic airway inflammation until the
effects (specific and off-target) and mechanisms are fully elu-
cidated.
In summary, our data suggest divergent role for arginase I
in allergic inflammation compared to parasitic responses.
Since arginase is a prominent product of alternatively acti-
vated macrophages, which are induced by IL-4 in both
allergic and parasitic responses, our data suggests alterna-
tively activated macrophages evolved to combat parasitic
infections and are either bystanders in allergic inflamma-
tion or have developed other effector molecules for aller-
gic Th2-associated responses.
Conclusion
Bone marrow cell derived arginase I is the predominant
source of allergen-induced lung arginase but is not
required for allergen-induced inflammation, airway
hyperresponsiveness or collagen deposition.
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